1
|
Caillot L, Leclerc M, Sleiman EJR, Sloma I, Wagner-Ballon O, Claudel A, Beckerich F, Redjoul R, Robin C, Parinet V, Pautas C, Menouche D, Bouledroua S, Cabanne L, Nait-Sidenas Y, Gautier E, Rouard H, Lafon I, Chalandon Y, Boissel N, Caillot D, Maury S. Long-term outcome after autologous BCR::ABL1-negative peripheral blood stem cell transplantation in adults with Philadelphia-positive acute lymphoblastic leukemia: a comparative study. Haematologica 2024; 109:1264-1268. [PMID: 38031800 PMCID: PMC10985448 DOI: 10.3324/haematol.2023.283742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 11/20/2023] [Indexed: 12/01/2023] Open
Abstract
Not available.
Collapse
Affiliation(s)
- Leo Caillot
- Hematology Department, CHU Francois Mitterrand, Dijon
| | - Mathieu Leclerc
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | | | - Ivan Sloma
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Orianne Wagner-Ballon
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Alexis Claudel
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Florence Beckerich
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Rabah Redjoul
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Christine Robin
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Vincent Parinet
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Cecile Pautas
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Dehbia Menouche
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Selwa Bouledroua
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Ludovic Cabanne
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Yakout Nait-Sidenas
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010
| | - Eric Gautier
- Etablissement Francais du Sang, Ile de France, UPEC University, Creteil, F-94010
| | - Helene Rouard
- Etablissement Francais du Sang, Ile de France, UPEC University, Creteil, F-94010
| | - Ingrid Lafon
- Hematology Department, CHU Francois Mitterrand, Dijon
| | - Yves Chalandon
- Division of Hematology, Department of Medical Specialties, University Hospital and University of Geneva, Geneva, Switzerland
| | - Nicolas Boissel
- AP-HP, Paris Cite University, Unite d'Hematologie Adolescents et Jeunes Adultes, Hopital Saint Louis, Paris
| | - Denis Caillot
- Hematology Department, CHU Francois Mitterrand, Dijon
| | - Sebastien Maury
- AP-HP, UPEC University, Henri Mondor Hospital, Hematology Department, Creteil, F-94010.
| |
Collapse
|
2
|
Longval T, Leprêtre AC, Ravinet A, Fayard A, Forcade E, Coman T, Redjoul R, Berceanu A, Buchbinder N, Berlie G, Mappoura M, Giannotti F, Chevillon F, Robin M, Peffault de Latour R, Sicre de Fontbrune F. Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC. Bone Marrow Transplant 2024:10.1038/s41409-024-02202-9. [PMID: 38461290 DOI: 10.1038/s41409-024-02202-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 12/15/2023] [Accepted: 01/08/2024] [Indexed: 03/11/2024]
Affiliation(s)
- Thomas Longval
- Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
| | | | - Aurélie Ravinet
- Hematology Department, Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, France
| | - Amandine Fayard
- Hematology Department, Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, France
| | - Edouard Forcade
- Hematology Department, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
| | - Tereza Coman
- Hematology Department, Gustave-Roussy, Villejuif, France
| | - Rabah Redjoul
- Hematology Department, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Ana Berceanu
- Hematology Department, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Nimrod Buchbinder
- Hematopoietic Pediatric Transplant Center, Centre Hospitalier Universitaire de Rouen, Rouen, France
| | | | - Maria Mappoura
- Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
| | - Federica Giannotti
- Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
| | - Florian Chevillon
- Hematology Adolescents and Young Adults, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Marie Robin
- Hematology Transplant Unit, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Régis Peffault de Latour
- Hematology Transplant Unit, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Flore Sicre de Fontbrune
- Hematology Transplant Unit, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
| |
Collapse
|
3
|
Redjoul R, Beckerich F, de Luna G, Leclerc M, Hebert N, Sloma I, Menouche D, Bartolucci P, Maury S. ABO blood barrier to engraftment after allogeneic stem cell transplantation in sickle cell disease: A case-story with two successive HLA-matched sibling donors. Am J Hematol 2023; 98:692-696. [PMID: 36510370 DOI: 10.1002/ajh.26808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 11/30/2022] [Accepted: 12/06/2022] [Indexed: 12/15/2022]
Affiliation(s)
- Rabah Redjoul
- Hematology Department, AP-HP, Hôpital Henri Mondor, Créteil, France
| | | | - Gonzalo de Luna
- AP-HP, Hôpital Henri Mondor, Unité des maladies génétiques du globule rouge and Etablissement Français du Sang, Créteil, France
| | - Mathieu Leclerc
- Hematology Department, AP-HP, Hôpital Henri Mondor, Créteil, France
- IMRB, INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| | - Nicolas Hebert
- AP-HP, Hôpital Henri Mondor, Unité des maladies génétiques du globule rouge and Etablissement Français du Sang, Créteil, France
| | - Ivan Sloma
- IMRB, INSERM U955, Paris Est Créteil University UPEC, Créteil, France
- Laboratoire d'onco-hématologie Moléculaire, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Dehbia Menouche
- Hematology Department, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Pablo Bartolucci
- AP-HP, Hôpital Henri Mondor, Unité des maladies génétiques du globule rouge and Etablissement Français du Sang, Créteil, France
- IMRB, INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| | - Sébastien Maury
- Hematology Department, AP-HP, Hôpital Henri Mondor, Créteil, France
- IMRB, INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| |
Collapse
|
4
|
Ahmed-Belkacem A, Redjoul R, Brillet R, Ahnou N, Leclerc M, López-Molina DS, Soulier A, Gourgeon A, Rodriguez C, Maury S, Pawlotsky JM, Fourati S. Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses. Viruses 2022; 14:v14091928. [PMID: 36146735 PMCID: PMC9506309 DOI: 10.3390/v14091928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 08/22/2022] [Accepted: 08/25/2022] [Indexed: 11/25/2022] Open
Abstract
Immunocompromised individuals generally fail to mount efficacious immune humoral responses following vaccination. The emergence of SARS-CoV-2 variants of concern has raised the question as to whether levels of anti-spike protein antibodies achieved after two or three doses of the vaccine efficiently protect against breakthrough infection in the context of immune suppression. We used a fluorescence-based neutralization assay to test the sensitivity of SARS-CoV-2 variants (ancestral variant, Beta, Delta, and Omicron BA.1) to the neutralizing response induced by vaccination in highly immunosuppressed allogeneic HSCT recipients, tested after two and three doses of the BNT162b2 vaccine. We show that neutralizing antibody responses to the Beta and Delta variants in most immunocompromised HSCT recipients increased after three vaccine doses up to values similar to those observed in twice-vaccinated healthy adults and were significantly lower against Omicron BA.1. Overall, neutralization titers correlated with the amount of anti-S-RBD antibodies measured by means of enzyme immunoassay, indicating that commercially available assays can be used to quantify the anti-S-RBD antibody response as a reliable surrogate marker of humoral immune protection in both immunocompetent and immunocompromised individuals. Our findings support the recommendation of additional early vaccine doses as a booster of humoral neutralizing activity against emerging variants, in HSCT immunocompromised patients. In the context of Omicron circulation, it further emphasizes the need for reinforcement of preventive measures including the administration of monoclonal antibodies in this high-risk population.
Collapse
Affiliation(s)
| | - Rabah Redjoul
- Haematology Department, Assistance Publique, Hôpitaux de Paris, Henri Mondor Hospital, 94000 Creteil, France
| | - Rozenn Brillet
- University Paris Est Créteil, INSERM U955, IMRB, 94010 Creteil, France
| | - Nazim Ahnou
- University Paris Est Créteil, INSERM U955, IMRB, 94010 Creteil, France
| | - Mathieu Leclerc
- University Paris Est Créteil, INSERM U955, IMRB, 94010 Creteil, France
- Haematology Department, Assistance Publique, Hôpitaux de Paris, Henri Mondor Hospital, 94000 Creteil, France
| | | | - Alexandre Soulier
- Department of Virology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, 94000 Creteil, France
| | - Aurélie Gourgeon
- Department of Virology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, 94000 Creteil, France
| | - Christophe Rodriguez
- University Paris Est Créteil, INSERM U955, IMRB, 94010 Creteil, France
- Department of Virology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, 94000 Creteil, France
| | - Sébastien Maury
- University Paris Est Créteil, INSERM U955, IMRB, 94010 Creteil, France
- Haematology Department, Assistance Publique, Hôpitaux de Paris, Henri Mondor Hospital, 94000 Creteil, France
| | - Jean-Michel Pawlotsky
- University Paris Est Créteil, INSERM U955, IMRB, 94010 Creteil, France
- Department of Virology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, 94000 Creteil, France
| | - Slim Fourati
- University Paris Est Créteil, INSERM U955, IMRB, 94010 Creteil, France
- Department of Virology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, 94000 Creteil, France
- Correspondence:
| |
Collapse
|
5
|
Fourati S, Robin C, Rodriguez C, Leclerc M, Beckerich F, Pawlotsky J, Redjoul R, Maury S. Breakthrough Covid‐19 infections in vaccinated recipients of allogeneic stem cell transplantation. eJHaem 2022; 3:980-982. [PMID: 35941883 PMCID: PMC9349499 DOI: 10.1002/jha2.512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 05/24/2022] [Accepted: 06/01/2022] [Indexed: 11/10/2022]
Affiliation(s)
- Slim Fourati
- Virology Department Assistance Publique‐Hôpitaux de Paris (AP‐HP) Henri Mondor Hospital Créteil France
- INSERM U955 Paris Est Créteil University UPEC Créteil France
| | - Christine Robin
- Hematology Department AP‐HP Fédération Hospitalo‐Universitaire TRUE InnovaTive theRapy for immUne disordErs Henri Mondor Hospital Créteil France
| | - Christophe Rodriguez
- Virology Department Assistance Publique‐Hôpitaux de Paris (AP‐HP) Henri Mondor Hospital Créteil France
- INSERM U955 Paris Est Créteil University UPEC Créteil France
| | - Mathieu Leclerc
- INSERM U955 Paris Est Créteil University UPEC Créteil France
- Hematology Department AP‐HP Fédération Hospitalo‐Universitaire TRUE InnovaTive theRapy for immUne disordErs Henri Mondor Hospital Créteil France
| | - Florence Beckerich
- Hematology Department AP‐HP Fédération Hospitalo‐Universitaire TRUE InnovaTive theRapy for immUne disordErs Henri Mondor Hospital Créteil France
| | - Jean‐Michel Pawlotsky
- Virology Department Assistance Publique‐Hôpitaux de Paris (AP‐HP) Henri Mondor Hospital Créteil France
- INSERM U955 Paris Est Créteil University UPEC Créteil France
| | - Rabah Redjoul
- Hematology Department AP‐HP Fédération Hospitalo‐Universitaire TRUE InnovaTive theRapy for immUne disordErs Henri Mondor Hospital Créteil France
| | - Sébastien Maury
- INSERM U955 Paris Est Créteil University UPEC Créteil France
- Hematology Department AP‐HP Fédération Hospitalo‐Universitaire TRUE InnovaTive theRapy for immUne disordErs Henri Mondor Hospital Créteil France
| |
Collapse
|
6
|
Robin C, Redjoul R, Terrade A, Deghmane AE, Cabanne L, Cordonnier C, Taha MK. Immunogenicity and safety of the meningococcal B recombinant (4CMenB) vaccine in allogeneic hematopoietic cell transplantation recipients. Clin Microbiol Infect 2022; 28:1609-1614. [PMID: 35803542 DOI: 10.1016/j.cmi.2022.06.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 06/16/2022] [Accepted: 06/21/2022] [Indexed: 11/03/2022]
Abstract
OBJECTIVES Despite a high risk of invasive meningococcal (Men) disease, there is no published data on any MenB vaccine after hematopoietic cell transplantation (HCT). We investigated the immunogenicity and safety of the 4CMenB recombinant vaccine (Bexsero®) in adult HCT recipients. METHODS Patients were eligible from 6 months post-HCT to receive 2 4CMenB doses at 2 months interval. Sera were collected at baseline, 1 month after the second dose, and 12 months after enrollment. The serum bactericidal activity (SBA) using human complement (hSBA) was assessed against fHbp, NadA, PorAP1.4 and NHBA antigens. The vaccine response was defined by one criteria for one vaccine antigen: (1) In patients with a hSBA titer < 4 at baseline: a titer > 4; (2) In patients with a hSBA titer > 4 at baseline: at least a x4 increase. RESULTS 40 patients were included at a median of 2.14 (0.57-13.03) years post-transplant. At baseline, most patients (32/40 80%) had hSBA titers < 4 for all vaccine antigens. After 2 vaccine doses, the proportion of patients with a titer > 4 was significantly increased for fHbp (23/40 57.5%), NadA (25/40 62.5%), and PorA (31/40 77.5%) but not for NHBA for which only 6/40 (15%) patients responded. 36/40 (90%) patients were responders to > 1 antigen. However, 9 months later, only 23/37 (62.2%) patients were still seroprotected. No severe adverse event was observed. CONCLUSION The response rate of 90% for >1 vaccine antigen and our safety data supports the 4CMenB vaccination of HCT recipients from 6 months after transplant with 2 doses. CLINICAL TRIALS REGISTRATION Clinicaltrials.gov, NCT03509051.
Collapse
Affiliation(s)
- Christine Robin
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France; University Paris-Est-Créteil, Créteil, France.
| | - Rabah Redjoul
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France
| | - Aude Terrade
- Institut Pasteur, Invasive bacterial infections Unit and National reference center for meningococci and Haemophilus influenzae, 28, rue du Dr Roux, Paris, France
| | - Ala-Eddine Deghmane
- Institut Pasteur, Invasive bacterial infections Unit and National reference center for meningococci and Haemophilus influenzae, 28, rue du Dr Roux, Paris, France
| | - Ludovic Cabanne
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France
| | - Catherine Cordonnier
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France; University Paris-Est-Créteil, Créteil, France.
| | - Muhamed-Kheir Taha
- Institut Pasteur, Invasive bacterial infections Unit and National reference center for meningococci and Haemophilus influenzae, 28, rue du Dr Roux, Paris, France
| |
Collapse
|
7
|
Moatti A, Debesset A, Pilon C, Beldi-Ferchiou A, Leclerc M, Redjoul R, Charlotte F, To NH, Bak A, Belkacemi Y, Salomon BL, Issa F, Michonneau D, Maury S, Cohen JL, Thiolat A. TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation. J Immunother Cancer 2022; 10:jitc-2021-003508. [PMID: 35387779 PMCID: PMC8987798 DOI: 10.1136/jitc-2021-003508] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/01/2022] [Indexed: 12/13/2022] Open
Abstract
Background Targeting immune checkpoints that inhibit antitumor immune responses has emerged as a powerful new approach to treat cancer. We recently showed that blocking the tumor necrosis factor receptor-type 2 (TNFR2) pathway induces the complete loss of the protective function of regulatory T cells (Tregs) in a model of graft-versus-host disease (GVHD) prevention that relies on Treg-based cell therapy. Here, we tested the possibility of amplifying the antitumor response by targeting TNFR2 in a model of tumor relapse following hematopoietic stem-cell transplantation, a clinical situation for which the need for efficient therapeutic options is still unmet. Method We developed appropriate experimental conditions that mimic patients that relapsed from their initial hematological malignancy after hematopoietic stem-cell transplantation. This consisted of defining in allogeneic bone marrow transplantation models developed in mice, the maximum number of required tumor cells and T cells to infuse into recipient mice to develop a model of tumor relapse without inducing GVHD. We next evaluated whether anti-TNFR2 treatment could trigger alloreactivity and consequently antitumor immune response. In parallel, we also studied the differential expression of TNFR2 on T cells including Treg from patients in post-transplant leukemia relapse and in patients developing GVHD. Results Using experimental conditions in which neither donor T cells nor TNFR2-blocking antibody per se have any effect on tumor relapse, we observed that the coadministration of a suboptimal number of T cells and an anti-TNFR2 treatment can trigger alloreactivity and subsequently induce a significant antitumor effect. This was associated with a reduced percentage of activated CD4+ and CD8+ Tregs. Importantly, human Tregs over-expressed TNFR2 relative to conventional T cells in healthy donors and in patients experiencing leukemia relapse or cortico-resistant GVHD after hematopoietic stem cell transplantation. Conclusions These results highlight TNFR2 as a new target molecule for the development of immunotherapies to treat blood malignancy relapse, used either directly in grafted patients or to enhance donor lymphocyte infusion strategies. More widely, they open the door for new perspectives to amplify antitumor responses against solid cancers by directly targeting Tregs through their TNFR2 expression.
Collapse
Affiliation(s)
- Audrey Moatti
- INSERM, IMRB, Université Paris-Est Créteil Val de Marne, Créteil, France.,CIC Biotherapy, GHU Chenevier Mondor, Créteil, France
| | - Anais Debesset
- INSERM, IMRB, Université Paris-Est Créteil Val de Marne, Créteil, France
| | | | | | - Mathieu Leclerc
- INSERM, IMRB, Université Paris-Est Créteil Val de Marne, Créteil, France.,Service d'hématologie Clinique, GHU Chenevier Mondor, Créteil, France
| | - Rabah Redjoul
- Service d'hématologie Clinique, GHU Chenevier Mondor, Créteil, France
| | - Frederic Charlotte
- Service d'anatomopathologie, University Hospital Pitié Salpêtrière, Paris, France
| | - Nhu Hanh To
- INSERM, IMRB, Université Paris-Est Créteil Val de Marne, Créteil, France.,Service d'oncologie-radiothérapie, GHU Chenevier Mondor, Créteil, France
| | - Adeline Bak
- Service d'oncologie-radiothérapie, GHU Chenevier Mondor, Créteil, France
| | - Yazid Belkacemi
- INSERM, IMRB, Université Paris-Est Créteil Val de Marne, Créteil, France.,Service d'oncologie-radiothérapie, GHU Chenevier Mondor, Créteil, France
| | - Benoît Laurent Salomon
- INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, Paris, France
| | - Fadi Issa
- Transplantation Research Immunology Group, University of Oxford Nuffield Department of Surgical Sciences, Oxford, UK
| | | | - Sebastien Maury
- INSERM, IMRB, Université Paris-Est Créteil Val de Marne, Créteil, France.,Service d'hématologie Clinique, GHU Chenevier Mondor, Créteil, France
| | - José Laurent Cohen
- INSERM, IMRB, Université Paris-Est Créteil Val de Marne, Créteil, France .,CIC Biotherapy, GHU Chenevier Mondor, Créteil, France
| | - Allan Thiolat
- INSERM, IMRB, Université Paris-Est Créteil Val de Marne, Créteil, France
| |
Collapse
|
8
|
Leclerc M, Redjoul R, Le Bouter A, Beckerich F, Robin C, Parinet V, Pautas C, Menouche D, Bouledroua S, Roy L, Cabanne L, Nait-Sidenas Y, Harfouch E, Gautier E, Fourati S, Maury S. Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT. The Lancet Haematology 2022; 9:e318-e321. [PMID: 35378072 PMCID: PMC8975260 DOI: 10.1016/s2352-3026(22)00097-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 03/14/2022] [Accepted: 03/16/2022] [Indexed: 01/07/2023]
Affiliation(s)
- Mathieu Leclerc
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France; INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| | - Rabah Redjoul
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France
| | - Anne Le Bouter
- Virology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Florence Beckerich
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France
| | - Christine Robin
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France
| | - Vincent Parinet
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France
| | - Cécile Pautas
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France; INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| | - Dehbia Menouche
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France
| | - Selwa Bouledroua
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France
| | - Lydia Roy
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France; INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| | - Ludovic Cabanne
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France
| | - Yakout Nait-Sidenas
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France
| | - Elham Harfouch
- Etablissement Français du Sang, Ile de France, Créteil, France
| | - Eric Gautier
- Etablissement Français du Sang, Ile de France, Créteil, France
| | - Slim Fourati
- INSERM U955, Paris Est Créteil University UPEC, Créteil, France; Virology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Sébastien Maury
- Haematology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération Hospitalo-Universitaire TRUE innovative therapy for immune disorders, Henri Mondor Hospital, Creteil 94000, France; INSERM U955, Paris Est Créteil University UPEC, Créteil, France.
| |
Collapse
|
9
|
Leclerc M, Redjoul R, Le Bouter A, Beckerich F, Robin C, Parinet V, Pautas C, Menouche D, Bouledroua S, Roy L, Cabanne L, Nait-Sidenas Y, Fourati S, Maury S. Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients. J Hematol Oncol 2022; 15:27. [PMID: 35303906 PMCID: PMC8931584 DOI: 10.1186/s13045-022-01250-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Accepted: 03/07/2022] [Indexed: 01/12/2023] Open
Abstract
Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRNA vaccine in HSCT recipients. We systematically proposed vaccination with BNT162b2 to HSCT recipients and gave a third vaccine dose to those showing titers of IgG(S-RBD) below 4160 AU/mL 1 month following the second dose. We then quantified anti-SARS-CoV-2 antibodies dynamics in 133 of these HSCT recipients (88 after two and 45 after three vaccine doses) 6 months after the first vaccine dose. Mean IgG(S-RBD) titer at 6 months was significantly lower than the peak value measured 1 month after a second (p < 0.001) or third (p < 0.01) vaccine dose. IgG(S-RBD) titers at 6 months were strongly correlated to peak values (p < 0.001) and a peak titer above 10,370 AU/mL predicted persistent protection at 6 months. Seventy-two percent (96/133) of patients retained protective antibody levels at 6 months. Immunosuppressive drugs and low lymphocyte counts in peripheral blood correlated with lower IgG(S-RBD) titers at 6 months. Four patients (3%) developed PCR-documented SARS-CoV-2 infection and one died.
Collapse
Affiliation(s)
- Mathieu Leclerc
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
- INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| | - Rabah Redjoul
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
| | - Anne Le Bouter
- Virology Department, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France
| | - Florence Beckerich
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
| | - Christine Robin
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
| | - Vincent Parinet
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
| | - Cécile Pautas
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
- INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| | - Dehbia Menouche
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
| | - Selwa Bouledroua
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
| | - Lydia Roy
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
- INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| | - Ludovic Cabanne
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
| | - Yakout Nait-Sidenas
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France
| | - Slim Fourati
- INSERM U955, Paris Est Créteil University UPEC, Créteil, France
- Virology Department, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France
| | - Sébastien Maury
- Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 51 avenue du Mal de Lattre de Tassigny, 94010, Créteil Cedex, France.
- INSERM U955, Paris Est Créteil University UPEC, Créteil, France.
| |
Collapse
|
10
|
Beauvais D, Robin C, Thiebaut A, Alain S, Coiteux V, Ducastelle-Lepretre S, Marçais A, Ceballos P, Xhaard A, Redjoul R, Nguyen S, Brissot E, Joris M, Turlure P, Rubio MT, Chevallier P, Bénard N, Liautard C, Yakoub-Agha I. Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program. J Clin Virol 2022; 148:105106. [PMID: 35182958 DOI: 10.1016/j.jcv.2022.105106] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2021] [Revised: 02/09/2022] [Accepted: 02/13/2022] [Indexed: 10/19/2022]
Abstract
We report the results of the French Temporary Authorization of Use (ATU) compassionate program of letermovir for primary prophylaxis conducted in 21 transplant centers. Patients were CMV seropositive allogeneic hematopoietic cell transplantation recipients and at high risk for CMV infection. Primary prophylaxis was defined as initiation of letermovir between day 0 and day +28 post-transplant. Between November 2017 and January 2019, 96 patients with a median age of 56 years received letermovir and follow-up data were available for 78 patients. The median time from transplant to letermovir initiation was 4 days, and the median duration of exposure to letermovir was 78 days, with 57 patients still on treatment at the cutoff date. Letermovir was temporarily discontinued in 4 patients (5.1%) and stopped in 39 patients (50.0%), in most cases due to planned end of treatment (n = 16, 20.5%). Fifteen patients (19.2%) each presented one positive CMV PCR, in median 13 days after letermovir initiation. Clinically significant CMV infection was reported in 5 patients (6.4%). No CMV disease was reported. At least one adverse drug reaction was reported for 12 patients (15.4%). In this early access program, letermovir was effective with comparable results of the phase 3 study with a low rate of clinically significant CMV infection, including in patients who were at high-risk for CMV infection.
Collapse
Affiliation(s)
- David Beauvais
- Univ Lille, CHU Lille, Hematology Department, Inserm, Infinite U1286, Lille, France.
| | - Christine Robin
- University Paris-Est-Créteil, Hematology Department, Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France
| | - Anne Thiebaut
- Hematology Department, CHU Grenoble, Grenoble, France
| | - Sophie Alain
- INSERM, CHU Limoges, RESINFIT, U1092, National Reference Center for Herpesviruses, Limoges University, Limoges, France
| | - Valérie Coiteux
- Univ Lille, CHU Lille, Hematology Department, Inserm, Infinite U1286, Lille, France
| | | | - Ambroise Marçais
- Department of adult hematology, Assistance Publique-Hôpitaux de Paris, university hospital Necker, Paris, France
| | - Patrice Ceballos
- Hematology Department, Saint-Eloi University Hospital, Montpellier, France
| | - Alienor Xhaard
- Hematology and transplantation unit, Saint Louis Hospital, APHP, Paris, France
| | - Rabah Redjoul
- University Paris-Est-Créteil, Hematology Department, Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France
| | - Stéphanie Nguyen
- Department of Hematology, AP-HP, Hôpital Pitié-Salpétrière, Sorbonne Université, Paris, France
| | - Eolia Brissot
- Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France
| | - Magalie Joris
- Department of Haematology, Amiens University Medical Center, Amiens, France
| | - Pascal Turlure
- CHU Limoges, Univ. Limoges, Department of Hematology, Limoges, France
| | | | | | | | | | - Ibrahim Yakoub-Agha
- Univ Lille, CHU Lille, Hematology Department, Inserm, Infinite U1286, Lille, France
| |
Collapse
|
11
|
Redjoul R, Le Bouter A, Parinet V, Fourati S, Maury S. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT. Lancet Haematol 2021; 8:e681-e683. [PMID: 34487683 PMCID: PMC8415894 DOI: 10.1016/s2352-3026(21)00274-x] [Citation(s) in RCA: 45] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 08/07/2021] [Accepted: 08/12/2021] [Indexed: 12/16/2022]
Affiliation(s)
- Rabah Redjoul
- Haematology Department, Assistance Publique, Hôpitaux de Paris, Henri Mondor Hospital, Créteil 94000, France
| | - Anne Le Bouter
- Virology Department, Assistance Publique, Hôpitaux de Paris, Henri Mondor Hospital, Créteil 94000, France
| | - Vincent Parinet
- Haematology Department, Assistance Publique, Hôpitaux de Paris, Henri Mondor Hospital, Créteil 94000, France
| | - Slim Fourati
- Virology Department, Assistance Publique, Hôpitaux de Paris, Henri Mondor Hospital, Créteil 94000, France; INSERM U955, Université Paris Est Créteil Val de Marne, Créteil, France
| | - Sébastien Maury
- Haematology Department, Assistance Publique, Hôpitaux de Paris, Henri Mondor Hospital, Créteil 94000, France; INSERM U955, Université Paris Est Créteil Val de Marne, Créteil, France.
| |
Collapse
|
12
|
Redjoul R, Le Bouter A, Beckerich F, Fourati S, Maury S. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet 2021; 398:298-299. [PMID: 34270933 PMCID: PMC8277189 DOI: 10.1016/s0140-6736(21)01594-4] [Citation(s) in RCA: 84] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 06/28/2021] [Accepted: 07/01/2021] [Indexed: 12/25/2022]
|
13
|
Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S. Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 2021; 62:1756-1760. [PMID: 33596765 DOI: 10.1080/10428194.2021.1881505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- S Fodil
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - E Raffoux
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - P Y Dumas
- Service d'Hématologie, CHU Bordeaux, F-33000, Bordeaux, France
| | - Y Desbrosses
- Service d'Hématologie, CHRU Jean Minjoz, Besançon, France
| | - F Larosa
- Service d'Hématologie, CHU de Dijon, Dijon, France
| | - S Chantepie
- Service d'Hématologie, Institut d'Hématologie de Basse-Normandie CHU de Caen, Caen, France
| | - M V Larcher
- Service d'Hématologie, Hospices civils de Lyon, CHU de Lyon, Lyon, France
| | - J B Mear
- Service d'Hématologie, CHU de Rennes - Hôpital Pontchaillou, Rennes, France
| | - P Peterlin
- Service d'Hématologie, CHU de Nantes, Nantes, France
| | - M Hunault-Berger
- Service des Maladies du Sang, Centre Hospitalier Universitaire, FHU GOAL, CRCINA, INSERM, Angers, France
| | - M A Hospital
- Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France
| | - V Morel
- Service d'Hématologie, Hôpital Pitié-Salpêtrière AP-HP, Paris, France
| | - N Lucas
- Service d'Hématologie, Institut Gustave Roussy, Villejuif, France
| | - V Vidal
- Service d'Hématologie, Hôpital Avicenne AP-HP, Bobigny, France
| | - C Salanoubat
- Service d'Hématologie, C.H. Sud Francilien, Corbeil-Essonnes, France
| | - J Michel
- Service d'Hématologie, C.H.R. - Hôpital Félix Maréchal, Metz-Thionville, France
| | - C Mediavilla
- Service d'Hématologie, Hôpital Saint-Antoine AP-HP, Paris, France
| | - M Ojeda-Uribe
- Service d'Hématologie, Groupe Hospitalier Régional Mulhouse Sud-Alsace, Mulhouse, France
| | - M Alexis
- Service d'Hématologie, CHR Orléans, Orléans, France
| | - J Frayfer
- Service d'Hématologie, Grand Hôpital de l'Est Francilien - Site de Meaux, Meaux, France
| | - M Carré
- Service d'Hématologie, CHU Grenoble Alpes, La Tronche, France
| | - N Maillard
- Service d'Hématologie, CHU de Poitiers, Poitiers, France
| | - R Redjoul
- Service d'Hématologie, CHU Henri Mondor, AP-HP et UPEC, Créteil, France
| | - A Banos
- Service d'Hématologie, Centre hospitalier de la côte basque, Bayonne, France
| | - M Detrait
- Service d'Hématologie, CHRU de Nancy, Nancy, France
| | - T Cluzeau
- Département d'Hématologie, Université Cote d'Azur, CHU de Nice, Nice, France
| | | | - D Chaoui
- Service d'Hématologie, CH d'Argenteuil, Argenteuil, France
| | - M Elassy
- Service d'Hématologie, CH d'Auxerre, Auxerre, France
| | - A Pigneux
- Service d'Hématologie, CHU Bordeaux, F-33000, Bordeaux, France
| | - H Dombret
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - C Récher
- Service d'Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France
| | - S Bertoli
- Service d'Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France
| | | |
Collapse
|
14
|
Robin C, Thiebaut A, Alain S, Sicre de Fontbrune F, Berceanu A, D'Aveni M, Ceballos P, Redjoul R, Nguyen-Quoc S, Bénard N, Pahlavan-Grumel G, Cordonnier C. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program. Biol Blood Marrow Transplant 2020; 26:978-984. [DOI: 10.1016/j.bbmt.2020.01.027] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Revised: 01/30/2020] [Accepted: 01/31/2020] [Indexed: 12/22/2022]
|
15
|
Robin C, Mariaggi AA, Redjoul R, Leclerc M, Beckerich F, Cabanne L, Pautas C, Maury S, Rozenberg F, Cordonnier C. Long-Term Immunity to Measles after Allogeneic Hematopoietic Cell Transplantation: Factors Associated with Seroprotection before Revaccination. Biol Blood Marrow Transplant 2020; 26:985-991. [DOI: 10.1016/j.bbmt.2020.02.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 01/26/2020] [Accepted: 02/03/2020] [Indexed: 10/25/2022]
|
16
|
Robin C, Bahuaud M, Redjoul R, Jeljeli M, Leclerc M, Cabanne L, Beckerich F, Pautas C, Maury S, Cordonnier C. Antipneumococcal Seroprotection Years After Vaccination in Allogeneic Hematopoietic Cell Transplant Recipients. Clin Infect Dis 2019; 71:e301-e307. [DOI: 10.1093/cid/ciz1168] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Accepted: 11/28/2019] [Indexed: 12/11/2022] Open
Abstract
Abstract
Background
International guidelines recommend vaccinating allogeneic hematopoietic cell transplant (HCT) recipients at 3 months after transplant, giving 3 doses of pneumococcal conjugate vaccine (PCV) followed by either a dose of 23-valent pneumococcal polysaccharide vaccine (PSV23) or a fourth PCV dose in the case of graft-versus-host disease (GvHD). However, the long-term immunity after this regimen is unknown, and there is no recommendation from 24 months after transplant regarding boosts. Our objective was to assess the antipneumococcal antibody titers and seroprotection rates of allogeneic HCT recipients years after different schedules of vaccination.
Methods
We assessed 100 adult HCT recipients a median of 9.3 years (range: 1.7–40) after transplant. All patients had received at least one dose of PCV and were assessed for antipneumococcal immunoglobulin G (IgG) antibody titers against the 7 serotypes shared by PCV7, PCV13, and PSV23. Sixty-six percent of the patients had been vaccinated according to the current guidelines.
Results
Considering an IgG titer ≥ 0.35 µg/mL as protective for each serotype, the seroprotection rate was 50% for 7/7 serotypes and 70% for 5/7 serotypes, with no differences between the different vaccination schedules. The lack of seroprotection was associated with a transplant performed not in complete remission or from a cord-blood unit, a relapse after transplant, or chronic GvHD at assessment.
Conclusion
Because only half of the vaccinated patients had long-term protection, pending prospective studies defining the best boost program after the initial one, we recommend the assessment of specific IgG titers starting from 24 months to decide for further doses.
Collapse
Affiliation(s)
- Christine Robin
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France
- University Paris-Est-Créteil, Créteil, France
| | - Mathilde Bahuaud
- APHP Cochin Hospital and University Paris-Descartes, Plateforme d’Immunomonitoring Vaccinal, Laboratoire d’Immunologie, Paris, France
| | - Rabah Redjoul
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France
| | - Mohamed Jeljeli
- APHP, Cochin Hospital and University Paris-Descartes, Laboratoire d’Immunologie, Institut Cochin, Paris, France
| | - Mathieu Leclerc
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France
- University Paris-Est-Créteil, Créteil, France
| | - Ludovic Cabanne
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France
| | - Florence Beckerich
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France
| | - Cécile Pautas
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France
| | - Sébastien Maury
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France
- University Paris-Est-Créteil, Créteil, France
| | - Catherine Cordonnier
- Assistance Publique-Hopitaux de Paris (AP-HP), Henri Mondor Hospital, Hematology Department, Creteil, France
- University Paris-Est-Créteil, Créteil, France
| |
Collapse
|
17
|
Robin C, Leclerc M, Angebault C, Redjoul R, Beckerich F, Cabanne L, Foulet F, Pautas C, Toma A, Maury S, Botterel F, Cordonnier C. Toxoplasmosis as an Early Complication of Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2019; 25:2510-2513. [DOI: 10.1016/j.bbmt.2019.07.035] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Revised: 07/22/2019] [Accepted: 07/26/2019] [Indexed: 11/30/2022]
|
18
|
Robin C, Lê MP, Melica G, Massias L, Redjoul R, Khoudour N, Leclerc M, Beckerich F, Maury S, Hulin A, Cordonnier C. Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. J Antimicrob Chemother 2018. [PMID: 28651341 DOI: 10.1093/jac/dkx198] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Objectives Atovaquone is one of the alternatives to trimethoprim/sulfamethoxazole for prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients. In volunteers, there was wide inter-individual variability in atovaquone bioavailability. The aim of this study was to assess the plasma concentrations of atovaquone in immunocompromised patients under PCP prophylaxis. Methods Adult haematology or HIV-positive patients receiving atovaquone (750 mg oral suspension twice a day) for PCP prophylaxis were included. Plasma concentrations were assessed using UV-HPLC, around 12 h after the evening dose (Cmin) and 1-5 h after the morning dose (Cmax). Results A total of 82 measurements were performed in 33 patients. This included 19 HSCT recipients, 7 haematology non-transplant patients and 7 HIV-positive patients. The median Cmin (IQR) was 11.3 μg/mL (6.2-27.8) and the median Cmax was 13.4 μg/mL (6.0-28.3). The Cmin and Cmax of atovaquone were not different between HIV-negative and HIV-positive patients, or between HSCT and non-HSCT patients. Atovaquone concentrations were not influenced by the co-administration of valaciclovir (n = 20) or ciclosporin (n = 11), by gut graft-versus-host disease (n = 7) or by the intake of atovaquone with food. Nineteen of the 33 (58%) patients had Cmin <15 μg/mL, a threshold associated with a low rate of clinical response in PCP treatment. Conclusions Atovaquone is poorly absorbed in more than half of immunocompromised patients and its bioavailability varies between individuals. These unpredictable variations raise the question of therapeutic drug monitoring, in order to identify patients with low concentrations and those who could benefit from regimen adaptation or from alternatives.
Collapse
Affiliation(s)
- Christine Robin
- Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Teaching Hospital, Department of Haematology, Créteil, France.,University Paris-Est Créteil (UPEC), Créteil, France
| | - Minh Patrick Lê
- APHP, Bichat-Claude Bernard Teaching Hospital, Pharmacology Laboratory, Paris, France.,IAME, Inserm UMR1137, Université Paris Diderot-Sorbonne Paris Cité, Paris, France
| | - Giovanna Melica
- AP-HP, Henri Mondor Teaching Hospital, Department of Clinical Immunology, Créteil, France
| | - Laurent Massias
- APHP, Bichat-Claude Bernard Teaching Hospital, Pharmacology Laboratory, Paris, France.,IAME, Inserm UMR1137, Université Paris Diderot-Sorbonne Paris Cité, Paris, France
| | - Rabah Redjoul
- Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Teaching Hospital, Department of Haematology, Créteil, France
| | - Nihel Khoudour
- AP-HP, Henri Mondor Teaching Hospital, Department of Pharmacology, Créteil, France
| | - Mathieu Leclerc
- Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Teaching Hospital, Department of Haematology, Créteil, France.,University Paris-Est Créteil (UPEC), Créteil, France
| | - Florence Beckerich
- Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Teaching Hospital, Department of Haematology, Créteil, France.,University Paris-Est Créteil (UPEC), Créteil, France
| | - Sébastien Maury
- Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Teaching Hospital, Department of Haematology, Créteil, France.,University Paris-Est Créteil (UPEC), Créteil, France
| | - Anne Hulin
- AP-HP, Henri Mondor Teaching Hospital, Department of Pharmacology, Créteil, France
| | - Catherine Cordonnier
- Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Teaching Hospital, Department of Haematology, Créteil, France.,University Paris-Est Créteil (UPEC), Créteil, France
| |
Collapse
|
19
|
Robin C, Hémery F, Dindorf C, Thillard J, Cabanne L, Redjoul R, Beckerich F, Rodriguez C, Pautas C, Toma A, Maury S, Durand-Zaleski I, Cordonnier C. Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients. BMC Infect Dis 2017; 17:747. [PMID: 29207952 PMCID: PMC5717816 DOI: 10.1186/s12879-017-2854-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Accepted: 11/24/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Cytomegalovirus (CMV) infection and disease (CMV episodes) are global concerns after allogeneic hematopoietic stem cell transplantation (HSCT). They affect survival, both by direct and indirect effects. Due to safety issues of current anti-CMV antivirals, long-term CMV prophylaxis is poorly tolerated and the most common strategy to decrease the incidence of CMV disease is preemptive. New, less toxic, molecules are currently being assessed for CMV prophylaxis which should replace or considerably decrease the preemptive approach. The aim of this study was to assess the economic burden of CMV episodes after HSCT with a preemptive approach. METHODS We analyzed data from 208 consecutive adults transplanted in our institution, between 2008 and 2013. Hospital resource utilization was retrieved via the linked hospital admissions and Diagnostic Related Groups for the period of conditioning to 12 months after transplant. RESULTS CMV episodes occurred in 70 patients (34%) over the first 12 months following HSCT, after a mean of 75 days (median: 46 (7-334)). The mean total length of stay was significantly associated with the occurrence of a CMV episode (113.9 vs. 87.5 days, p = 0.0002) but was associated neither with the pre-transplant CMV serology of donors/recipients nor with survival. The mean cost of transplant was €104,016 (SD = €37,281) after 12 months. Bivariate and multivariate analyses indicated that the occurrence of >1 CMV episode increased the costs of allogeneic HSCT by 25-30% (p < 0.0001). CONCLUSION Our study, which is the largest, single-institution cost study of allogeneic HSCT in Europe, shows that two or more CMV episodes significantly increased the transplant cost. New prophylactic strategies to prevent CMV infection and disease should decrease transplant costs.
Collapse
Affiliation(s)
- Christine Robin
- Department of Hematology, Assistance Publique-Hopitaux de Paris (APHP), Henri Mondor Teaching Hospital, 94010, Créteil, France.,University Paris-Est Créteil (UPEC), 94000, Créteil, France
| | - François Hémery
- Department of Medical Information, APHP, Henri Mondor Teaching Hospital, Créteil, France
| | | | | | - Ludovic Cabanne
- Department of Hematology, Assistance Publique-Hopitaux de Paris (APHP), Henri Mondor Teaching Hospital, 94010, Créteil, France
| | - Rabah Redjoul
- Department of Hematology, Assistance Publique-Hopitaux de Paris (APHP), Henri Mondor Teaching Hospital, 94010, Créteil, France
| | - Florence Beckerich
- Department of Hematology, Assistance Publique-Hopitaux de Paris (APHP), Henri Mondor Teaching Hospital, 94010, Créteil, France.,University Paris-Est Créteil (UPEC), 94000, Créteil, France
| | - Christophe Rodriguez
- University Paris-Est Créteil (UPEC), 94000, Créteil, France.,Department of Virology, and INSERM U955 Team 18, APHP, Henri Mondor Teaching Hospital, 94000, Créteil, France
| | - Cécile Pautas
- Department of Hematology, Assistance Publique-Hopitaux de Paris (APHP), Henri Mondor Teaching Hospital, 94010, Créteil, France
| | - Andrea Toma
- Department of Hematology, Assistance Publique-Hopitaux de Paris (APHP), Henri Mondor Teaching Hospital, 94010, Créteil, France
| | - Sébastien Maury
- Department of Hematology, Assistance Publique-Hopitaux de Paris (APHP), Henri Mondor Teaching Hospital, 94010, Créteil, France.,University Paris-Est Créteil (UPEC), 94000, Créteil, France
| | - Isabelle Durand-Zaleski
- University Paris-Est Créteil (UPEC), 94000, Créteil, France.,Department of Public Health, APHP, Henri Mondor Teaching Hospital, 94000-, Créteil, France
| | - Catherine Cordonnier
- Department of Hematology, Assistance Publique-Hopitaux de Paris (APHP), Henri Mondor Teaching Hospital, 94010, Créteil, France. .,University Paris-Est Créteil (UPEC), 94000, Créteil, France.
| |
Collapse
|
20
|
Robin C, Alanio A, Gits-Muselli M, la Martire G, Schlemmer F, Botterel F, Angebault C, Leclerc M, Beckerich F, Redjoul R, Pautas C, Toma A, Maury S, Bretagne S, Cordonnier C. Molecular Demonstration of a Pneumocystis Outbreak in Stem Cell Transplant Patients: Evidence for Transmission in the Daycare Center. Front Microbiol 2017; 8:700. [PMID: 28484441 PMCID: PMC5401873 DOI: 10.3389/fmicb.2017.00700] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2017] [Accepted: 04/05/2017] [Indexed: 12/24/2022] Open
Abstract
Pneumocystis jirovecii pneumonia (PCP) is a life-threatening infection in hematology. Although occasionally reported, the role of interhuman transmission of P. jirovecii in PCP, compared to that of reactivation, remains an unresolved question; the recommendation to isolate PCP patients in the hematology ward are not well evidence-based. Following an unexpected increase in the number of febrile pneumonia patients with P. jirovecii DNA detected in respiratory samples in our hematology ward, we explored 12 consecutive patients from November 2015 to May 2016. Genotyping of P jirovecii was performed using microsatellite markers. The frequency of simultaneous occupancy of these 12 patients in the same unit on the same day from 4 months prior to the first diagnosis was recorded. In three patients, the P. jirovecii genotype could not be determined because DNA was insufficient. One rare single genotype (Gt2) was found in four of the other nine, all allogeneic stem cell transplant recipients. The transmission map showed that these 4 patients had multiple opportunities to meet on the same day (median, 6.5; range, 4–10) at the daycare center. It was much less among the eight non-Gt2 patients (median, 1; range, 0–9; P = 0.048). This study, based on modern molecular technics, strongly suggests that interhuman transmission of P. jirovecii between allogeneic stem cell transplant recipients is possible. P. jirovecii DNA detected in respiratory specimens supports that isolation and respiratory precautions be recommended in such cases in the hematology ward.
Collapse
Affiliation(s)
- Christine Robin
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France.,Paris-Est Créteil UniversityCréteil, France
| | - Alexandre Alanio
- Parasitology-Mycology Laboratory, Assistance Publique-Hôpitaux de Paris, Lariboisière Saint-Louis Fernand Widal HospitalParis, France.,Paris-Diderot, Sorbonne Paris Cité UniversityParis, France.,Molecular Mycology Unit, National Reference Center of Invasive Mycosis and Antifungals, Centre National de la Recherche Scientifique, Institut Pasteur, URA3012Paris, France
| | - Maud Gits-Muselli
- Parasitology-Mycology Laboratory, Assistance Publique-Hôpitaux de Paris, Lariboisière Saint-Louis Fernand Widal HospitalParis, France.,Paris-Diderot, Sorbonne Paris Cité UniversityParis, France
| | - Giulia la Martire
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France
| | - Frédéric Schlemmer
- Paris-Est Créteil UniversityCréteil, France.,Unit of Pneumology, Intensive Care Department, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching Hospital, DHU A-TVBCréteil, France
| | - Françoise Botterel
- Paris-Est Créteil UniversityCréteil, France.,Parasitology-Mycology Laboratory, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France
| | - Cécile Angebault
- Paris-Est Créteil UniversityCréteil, France.,Parasitology-Mycology Laboratory, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France
| | - Mathieu Leclerc
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France.,Paris-Est Créteil UniversityCréteil, France
| | - Florence Beckerich
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France.,Paris-Est Créteil UniversityCréteil, France
| | - Rabah Redjoul
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France.,Paris-Est Créteil UniversityCréteil, France
| | - Cécile Pautas
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France
| | - Andrea Toma
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France
| | - Sébastien Maury
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France.,Paris-Est Créteil UniversityCréteil, France
| | - Stéphane Bretagne
- Parasitology-Mycology Laboratory, Assistance Publique-Hôpitaux de Paris, Lariboisière Saint-Louis Fernand Widal HospitalParis, France.,Paris-Diderot, Sorbonne Paris Cité UniversityParis, France.,Molecular Mycology Unit, National Reference Center of Invasive Mycosis and Antifungals, Centre National de la Recherche Scientifique, Institut Pasteur, URA3012Paris, France
| | - Catherine Cordonnier
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching HospitalCréteil, France.,Paris-Est Créteil UniversityCréteil, France
| |
Collapse
|
21
|
Al Dweik B, Redjoul R, Bastuji-Garin S, Beckerich F, Robin C, Pautas C, Toma A, Cabanne L, Maury S, Cordonnier C. Profound lymphopenia is associated with a lower risk of hepatic cytolysis during antithymocyte globulin administration. Am J Hematol 2016; 91:E276-8. [PMID: 26799506 DOI: 10.1002/ajh.24309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2016] [Revised: 01/12/2016] [Accepted: 01/14/2016] [Indexed: 11/07/2022]
Affiliation(s)
- Bashar Al Dweik
- Department of Hematology, Henri Mondor Teaching Hospital; Assistance Publique-Hôpitaux De Paris (AP-HP); Creteil France
| | - Rabah Redjoul
- Department of Hematology, Henri Mondor Teaching Hospital; Assistance Publique-Hôpitaux De Paris (AP-HP); Creteil France
| | - Sylvie Bastuji-Garin
- Department of Public Health; AP-HP, Henri Mondor Teaching Hospital; Créteil France
- CEpiA (Clinical Epidemiology and Ageing) Unit EA 7376; UPEC, DHU A-TVB, IMRB; Créteil France
| | - Florence Beckerich
- Department of Hematology, Henri Mondor Teaching Hospital; Assistance Publique-Hôpitaux De Paris (AP-HP); Creteil France
- Paris-Est Créteil University (UPEC); Créteil France
| | - Christine Robin
- Department of Hematology, Henri Mondor Teaching Hospital; Assistance Publique-Hôpitaux De Paris (AP-HP); Creteil France
- Paris-Est Créteil University (UPEC); Créteil France
| | - Cécile Pautas
- Department of Hematology, Henri Mondor Teaching Hospital; Assistance Publique-Hôpitaux De Paris (AP-HP); Creteil France
| | - Andréa Toma
- Department of Hematology, Henri Mondor Teaching Hospital; Assistance Publique-Hôpitaux De Paris (AP-HP); Creteil France
| | - Ludovic Cabanne
- Department of Hematology, Henri Mondor Teaching Hospital; Assistance Publique-Hôpitaux De Paris (AP-HP); Creteil France
| | - Sébastien Maury
- Department of Hematology, Henri Mondor Teaching Hospital; Assistance Publique-Hôpitaux De Paris (AP-HP); Creteil France
- Paris-Est Créteil University (UPEC); Créteil France
| | - Catherine Cordonnier
- Department of Hematology, Henri Mondor Teaching Hospital; Assistance Publique-Hôpitaux De Paris (AP-HP); Creteil France
- Paris-Est Créteil University (UPEC); Créteil France
| |
Collapse
|
22
|
Delbos F, Barhoumi W, Cabanne L, Beckerich F, Robin C, Redjoul R, Astati S, Toma A, Pautas C, Ansart-Pirenne H, Cordonnier C, Bierling P, Maury S. Donor Immunization Against Human Leukocyte Class II Antigens is a Risk Factor for Graft-versus-Host Disease. Biol Blood Marrow Transplant 2016; 22:292-299. [DOI: 10.1016/j.bbmt.2015.09.027] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 09/25/2015] [Indexed: 12/20/2022]
|
23
|
El Maaroufi H, Goubard A, Redjoul R, Legrand P, Pautas C, Mikdame M, Doghmi K, Toma A, Maury S, Schwarzinger M, Cordonnier C. Risk factors and scoring system for predicting bacterial resistance to cefepime as used empirically in haematology wards. Biomed Res Int 2015; 2015:945769. [PMID: 26075276 PMCID: PMC4436445 DOI: 10.1155/2015/945769] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Accepted: 04/04/2015] [Indexed: 02/06/2023]
Abstract
OBJECTIVES Bacterial resistance is of growing concern in haematology wards. As the inappropriate administration of empirical antibacterial may alter survival, we studied risk factors for resistance to our usual empirical first-line antibacterial therapy, cefepime. METHODS We retrospectively studied 103 first episodes of bacteraemia recorded in our haematology department over 2.5 years. Risk factors for cefepime-resistance were identified by multivariate logistic regression with backward selection (P < 0.05). A scoring system for predicting cefepime-resistance was built on independent factor, with an internal validation by the bootstrap resampling technique. RESULTS 38 (37%) episodes were due to Gram-negative bacteria. Fifty (49%) were due to bacteria resistant to cefepime. Cefepime resistance was significantly associated with a decreased survival at day 30 (P < 0.05). Three risk factors were independently associated with cefepime-resistance: acute lymphoblastic leukaemia; ≥18 days since hospital admission; and receipt of any β-lactam in the last month. Patients with ≥2 of these risk factors had a probability of 86% (CI 95%, 25 to 100%) to carry a cefepime-resistant strain. CONCLUSION Using our scoring system should reduce the indication of very broad antibacterial regimens in the empirical, first-line treatment of febrile hematology patients in more than 80% of the cases.
Collapse
Affiliation(s)
- Hicham El Maaroufi
- Assistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France
- Haematology Department, Hôpital Militaire d'Instruction Mohamed V, Rabat, Morocco
| | - Agathe Goubard
- Microbiology Laboratory, Henri Mondor Hospital, 94000 Créteil, France
| | - Rabah Redjoul
- Assistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France
| | - Patrick Legrand
- Microbiology Laboratory, Henri Mondor Hospital, 94000 Créteil, France
| | - Cécile Pautas
- Assistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France
| | - Mohamed Mikdame
- Haematology Department, Hôpital Militaire d'Instruction Mohamed V, Rabat, Morocco
| | - Kamal Doghmi
- Haematology Department, Hôpital Militaire d'Instruction Mohamed V, Rabat, Morocco
| | - Andréa Toma
- Assistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France
| | - Sébastien Maury
- Assistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France
| | - Michael Schwarzinger
- Equipe ATIP/AVENIR, INSERM, UMR 738, 75018 Paris, France
- University Paris Diderot, Sorbonne Paris Cité, UMR 738, 75018 Paris, France
| | - Catherine Cordonnier
- Assistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France
| |
Collapse
|
24
|
Guillaume T, Beguin Y, Tabrizi R, Nguyen S, Blaise D, Deconinck E, Redjoul R, Cornillon J, Guillerm G, Contentin N, Sirvent A, Turlure P, Salmon A, Huynh A, François S, Peffault de Latour R, Yakoub-Agha I, Mohty M. Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC). Eur J Haematol 2014; 94:265-9. [PMID: 25130897 DOI: 10.1111/ejh.12430] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/04/2014] [Indexed: 11/30/2022]
Abstract
T-prolymphocytic leukemia (T-PLL), a rare aggressive mature T-cell disorder, remains frequently resistant to conventional chemotherapy. Studies have suggested that allogeneic hematopoietic stem cell transplantation (HSCT) might possibly serve to consolidate the response to initial chemotherapy. The current report summarizes the outcome of 27 T-PLL cases identified in the registry in French Society for stem cell transplantation (SFGM-TC). Prior to HSCT, 14 patients were in complete remission (CR), 10 in partial response, three refractory, or in progression. Following HSCT, 21 patients achieved CR as best response. With a median follow-up for surviving patients of 33 (range, 6-103) months, 10 patients are still alive in continuous CR. Overall survival and progression-free survival estimates at 3 yr were 36% (95% CI: 17-54%) and 26% (95% CI: 14-45%), respectively. The relapse incidence after HSCT was 47% occurring at a median of 11.7 (range, 2-24) months. Overall cumulative incidence of transplant-related mortality was 31% at 3 yr. These results suggest that HSCT may allow long-term survival in patients with T-PLL following induction treatment; however, it is associated with a significant rate of toxicity.
Collapse
|
25
|
Maury S, Redjoul R, Cabanne L, Vigouroux S, Legros L, Cohen JL. Regulatory T-cell depletion in donor lymphocyte infusions for haematological malignancies: long-term outcomes from a prospective study. Br J Haematol 2014; 166:452-5. [DOI: 10.1111/bjh.12856] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Sébastien Maury
- Clinical Haematology; AP-HP, Hôpital Henri Mondor; Université Paris-Est Créteil Val de Marne (UPEC); Créteil France
- IMRB UPEC/INSERM U955 team 21; Bordeaux France
| | - Rabah Redjoul
- Clinical Haematology; AP-HP, Hôpital Henri Mondor; Université Paris-Est Créteil Val de Marne (UPEC); Créteil France
| | - Ludovic Cabanne
- Clinical Haematology; AP-HP, Hôpital Henri Mondor; Université Paris-Est Créteil Val de Marne (UPEC); Créteil France
| | | | | | - José L. Cohen
- IMRB UPEC/INSERM U955 team 21; Bordeaux France
- AP-HP, Center for Clinical Investigation in Biotherapy; UPEC; Créteil France
| |
Collapse
|
26
|
Sujobert P, Cuccuini W, Vignon-Pennamen D, Martin-Garcia N, Albertini AF, Uzunov M, Redjoul R, Dombret H, Raffoux E. Evidence of differentiation in myeloid malignancies associated neutrophilic dermatosis: a fluorescent in situ hybridization study of 14 patients. J Invest Dermatol 2012. [PMID: 23190893 DOI: 10.1038/jid.2012.408] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
27
|
Redjoul R, Toma A, Hicheri Y, Maaroufi HE, Maertens J, Vigouroux S, Lioure B, Machaczka M, Pautas C, Bories D, Wagner-Ballon O, Gaulard P, Martin-Garcia N, Maury S, Cordonnier C. Hemophagocytic syndrome after allogeneic hematopoietic cell transplantation: more a graft rejection than an infectious process? Eur J Haematol 2012; 88:458-60. [DOI: 10.1111/j.1600-0609.2012.01757.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|